Dr. Reddy’s Laboratories Announces the Launch of Neostigmine Methylsulfate Injection

Dr. Reddy’s Laboratories Ltd. announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection approved by the US Food and Drug Administration (USFDA). The Bloxiverz brand and generic had US sales of approximately USD 111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health. Dr. Reddy’s Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 mL and 10 mg/10 mL multi-dose vials. Bloxiverz is a registered trademark of Avadel Legacy Pharmaceuticals LLC. – Medical Buyer Bureau